NCT01985828View on ClinicalTrials.gov

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

November 19, 2013

Primary Completion Date

September 30, 2018

Study Completion Date

August 31, 2019

Conditions
Prostate Adenocarcinoma
Interventions
RADIATION

CyberKnife

OTHER

Androgen Deprivation Therapy (ADT)

RADIATION

Intensity Modulated radiation therapy (IMRT)

Per current standard of care

Trial Locations (1)

60068

Advocate Lutheran General Hospital, Park Ridge

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT01985828 - CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer | Biotech Hunter | Biotech Hunter